A Non-Randomized Study of the NightHawk Peripheral Plaque Excision System During Plaque Excision of Peripheral Arterial Disease (NightHawk)

This study has been terminated.
Information provided by:
FoxHollow Technologies
ClinicalTrials.gov Identifier:
First received: August 13, 2007
Last updated: January 16, 2008
Last verified: January 2008
To assess the proximity of the catheter to the vessel wall and to correlate excised tissue with images collected by the integrated Optical coherence Tomography (OCT) imaging system. The primary endpoints are correlation between OCT images and histological characterization of excised tissue.

Condition Intervention Phase
Peripheral Vascular Diseases
Device: NightHawk
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Non-Randomized Study of the NightHawk Peripheral Plaque Excision System During Plaque Excision of Peripheral Arterial Disease

Resource links provided by NLM:

Further study details as provided by FoxHollow Technologies:

Estimated Enrollment: 100
Study Start Date: August 2007
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient requires treatment for peripheral arterial disease (PAD).
  2. Patient is willing and able to provide Informed Consent.
  3. Patient has at least one focal, de novo infrainguinal lesion in a native vessel.
  4. The minimum reference vessel diameter is 2.0 - 4.5 mm, dependent on the NightHawk device used.
  5. The lesion is ≥ 50% stenosed by quantitative vascular angiography.
  6. The lesion is ≤ 7 cm in length.
  7. The patient must be able to take at least one form of anti-platelet or anti-thrombotic therapy.

Exclusion Criteria:

  1. Patient presents with degree of limb disease or a co-existing medical condition that makes revascularization inappropriate.
  2. The patient has diffuse peripheral arterial disease and/or the disease is heavily calcified.
  3. Patient presents with concomitant disease contraindicating an endovascular intervention.
  4. Patient is pregnant.
  5. The patient has a hypersensitivity to contrast materials that cannot be adequately pretreated.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00516308

United States, Texas
Austin Heart
Austin, Texas, United States, 78756
Sponsors and Collaborators
FoxHollow Technologies
  More Information

ClinicalTrials.gov Identifier: NCT00516308     History of Changes
Other Study ID Numbers: FHT-P-07-004 
Study First Received: August 13, 2007
Last Updated: January 16, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by FoxHollow Technologies:
Critical Limb Ischemia
Paripheral Arterial Disease
Leg pain

Additional relevant MeSH terms:
Peripheral Arterial Disease
Peripheral Vascular Diseases
Vascular Diseases
Arterial Occlusive Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on May 23, 2016